These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38236117)
21. А FLAVOUR OF DEATH: PERINDOPRIL INDUCED THICK MELANOMA AND BCC OF THE BACK. POTENTIAL ROLE OF THE GENERIC SUBSTANCE OR/-AND POSSIBLE NITROSAMINE CONTAMINATION AS SKIN CANCER KEY TRIGGERING FACTORS. Tchernev G Georgian Med News; 2023 Mar; (336):123-125. PubMed ID: 37166894 [TBL] [Abstract][Full Text] [Related]
22. MUSTARDE ROTATION FLAP AS ADEQUATE OPTION FOR HIGH-RISK BCC NEAR THE LOWER EYE LID: THE ADDITIONAL INTAKE OF N-NITROSO-FOLIC-ACID AND N-NITROSO-RIVOROXABAN AS COFACTORS/TRIGGERS OF THE METABOLIC REPROGRAMMING OF THE FUTURE CANCER CELL. Tchernev G; Ivanov L Georgian Med News; 2024 Jun; (351):131-137. PubMed ID: 39230235 [TBL] [Abstract][Full Text] [Related]
23. Telmisartan (and/or nitrosamine) - induced occult melanoma: first reported case in world literature. Tchernev G; Bitolska A; Patterson JW Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1075-1080. PubMed ID: 34085580 [No Abstract] [Full Text] [Related]
24. MULTIPLE KERATINOCYTIC CANCERS AFTER ENALAPRIL/LOSARTAN INTAKE: POTENTIAL LINKS TO DRUG MEDIATED NITROSOGENESIS/CARCINOGENESIS: MELOLABIAL ADVANCED FLAP AND UNDERMINING SURGERY AS OPTIMAL THERAPEUTIC APPROACH. Tchernev G Georgian Med News; 2023 Nov; (344):196-199. PubMed ID: 38236123 [TBL] [Abstract][Full Text] [Related]
25. METATYPICAL BCCS OF THE NOSE TREATED SUCCESSFULLY VIA BILOBED TRANSPOSITION FLAP: NITROSAMINES IN ACES (ENALAPRIL), ARBS (LOSARTAN) AS POSSIBLE SKIN CANCER KEY TRIGGERING FACTOR. Tchernev G; Kordeva S; Lozev I Georgian Med News; 2023 Feb; (335):22-25. PubMed ID: 37042583 [TBL] [Abstract][Full Text] [Related]
26. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805 [TBL] [Abstract][Full Text] [Related]
27. Quantum Mechanical Assessment of Nitrosamine Potency. De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898 [TBL] [Abstract][Full Text] [Related]
28. The dysplastic nevus: recognition and management. Barnhill RL; Hurwitz S; Duray PH; Arons MS Plast Reconstr Surg; 1988 Feb; 81(2):280-9. PubMed ID: 3275948 [TBL] [Abstract][Full Text] [Related]
29. Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine. Jolly RA; Cornwell PD; Noteboom J; Sayyed FB; Thapa B; Buckley LA Regul Toxicol Pharmacol; 2024 Sep; 152():105672. PubMed ID: 38968965 [TBL] [Abstract][Full Text] [Related]
30. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis. Hecht SS Proc Soc Exp Biol Med; 1997 Nov; 216(2):181-91. PubMed ID: 9349687 [TBL] [Abstract][Full Text] [Related]
31. KARAPANDZIC FLAP FOR SQUAMOUS CELL CARCINOMA OF THE LOWER LIPP: POTENTIAL ROLE OF NITROSAMINES IN EPROSARTAN AS CANCER TRIGGERING FACTORS. Tchernev G; Lozev I; Pidakev I; Kordeva S Georgian Med News; 2023 Jan; (334):83-85. PubMed ID: 36864798 [TBL] [Abstract][Full Text] [Related]
32. Irbesartan Induced Cutaneous Melanoma! Second Case in the Medical Literature! Tchernev G; Temelkova I Open Access Maced J Med Sci; 2019 Jan; 7(1):121-123. PubMed ID: 30740174 [TBL] [Abstract][Full Text] [Related]
33. Telmisartan/hydrochlorothiazide-induced nevus-associated cutaneous melanoma: first report in the medical literature. Tchernev G; Patterson JW Expert Rev Clin Pharmacol; 2021 Mar; 14(3):289-293. PubMed ID: 33576302 [No Abstract] [Full Text] [Related]
34. Human melanocytic neoplasms and their etiologic relationship with sunlight. Elder DE J Invest Dermatol; 1989 May; 92(5 Suppl):297S-303S. PubMed ID: 2654303 [TBL] [Abstract][Full Text] [Related]
35. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia. Clark WH; Hood AF; Tucker MA; Jampel RM Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124 [TBL] [Abstract][Full Text] [Related]
36. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases. Boyd AS; Shakhtour B; Shyr Y J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467 [TBL] [Abstract][Full Text] [Related]
37. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities. Bharate SS J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513 [TBL] [Abstract][Full Text] [Related]
38. Dermatoscopy of "dysplastic nevi": a beacon in diagnostic darkness. Roesch A; Burgdorf W; Stolz W; Landthaler M; Vogt T Eur J Dermatol; 2006; 16(5):479-93. PubMed ID: 17101467 [TBL] [Abstract][Full Text] [Related]
39. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. Tucker MA; Halpern A; Holly EA; Hartge P; Elder DE; Sagebiel RW; Guerry D; Clark WH JAMA; 1997 May; 277(18):1439-44. PubMed ID: 9145715 [TBL] [Abstract][Full Text] [Related]
40. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Banky JP; Kelly JW; English DR; Yeatman JM; Dowling JP Arch Dermatol; 2005 Aug; 141(8):998-1006. PubMed ID: 16103329 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]